Literature DB >> 8407246

Foamy viruses.

D Neumann-Haefelin1, U Fleps, R Renne, M Schweizer.   

Abstract

Foamy viruses share complex genome organization with lentiviruses and certain oncoviruses. The open reading frame 3' of env encodes a transcriptional transactivator. Distinct responsive sequences were identified in the long terminal repeats (LTRs) of simian (SFV-1 and SFV-3) and human foamy viruses (HFV). Transactivation of heterologous LTRs was described including those of simian and human immunodeficiency viruses. Foamy viruses persist for the whole lifetime in infected hosts (primates, cats, hamsters, cattle, and probably other mammals). The virus may be orally shed and transmitted, while being latent in various internal organs. Selective viral gene expression in the brains of mice transgenic for HFV has suggested a particular relationship to neural tissue. In latently SFV-3-infected cultured cells, methylation of proviral DNA is apparently involved in the control of latency. Demethylation as well as transfection with the transactivator were shown to be instrumental in viral reactivation. Natural infections with foamy viruses are common, elicit strong immune responses, and seem to be asymptomatic in nonhuman primates. Detection of such infections, however, may not be a triviality in man. While accidental transmission of foamy viruses to man is well documented, reported seroprevalence in human populations and the association of HFV with specific pathology (e.g. thyroiditis de Quervain, amyotrophic lateral sclerosis, and Graves' disease) are controversial and remain to be proven.

Entities:  

Mesh:

Year:  1993        PMID: 8407246     DOI: 10.1159/000150310

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  17 in total

1.  An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes.

Authors:  P A Goepfert; K Shaw; G Wang; A Bansal; B H Edwards; M J Mulligan
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Restriction of foamy viruses by APOBEC cytidine deaminases.

Authors:  Frédéric Delebecque; Rodolphe Suspène; Sara Calattini; Nicoletta Casartelli; Ali Saïb; Alain Froment; Simon Wain-Hobson; Antoine Gessain; Jean-Pierre Vartanian; Olivier Schwartz
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 3.  Foamy viruses are unconventional retroviruses.

Authors:  M L Linial
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

4.  A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum.

Authors:  P A Goepfert; K L Shaw; G D Ritter; M J Mulligan
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus.

Authors:  J A Mikovits; P M Hoffman; A Rethwilm; F W Ruscetti
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Nuclear localization of foamy virus Gag precursor protein.

Authors:  A W Schliephake; A Rethwilm
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Simian foamy virus isolated from an accidentally infected human individual.

Authors:  M Schweizer; V Falcone; J Gänge; R Turek; D Neumann-Haefelin
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  The nucleotide sequence and spliced pol mRNA levels of the nonprimate spumavirus bovine foamy virus.

Authors:  D L Holzschu; M A Delaney; R W Renshaw; J W Casey
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Efficient intracellular retrotransposition of an exogenous primate retrovirus genome.

Authors:  M Heinkelein; T Pietschmann; G Jármy; M Dressler; H Imrich; J Thurow; D Lindemann; M Bock; A Moebes; J Roy; O Herchenröder; A Rethwilm
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

10.  Gamma interferon is a major suppressive factor produced by activated human peripheral blood lymphocytes that is able to inhibit foamy virus-induced cytopathic effects.

Authors:  V Falcone; M Schweizer; A Toniolo; D Neumann-Haefelin; A Meyerhans
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.